Results 151 to 160 of about 73,182 (252)
Programmable mRNA‐nanobody platforms integrate compact VHH‐based targeting, transient mRNA expression, and adaptable CAR engineering to address major barriers to CAR‐T therapy in solid tumors. Their modular design enables flexible antigen recognition, controllable therapeutic activity, and potential adaptation to tumor evolution, providing an emerging ...
Li Ma +12 more
wiley +1 more source
Soluble CTLA-4 as a context-dependent immune checkpoint: biology, biomarker potential, and therapeutic implications. [PDF]
Cai X +5 more
europepmc +1 more source
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet +36 more
wiley +1 more source
The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications
1. This paper proposes the “oncobiome” as a unifying conceptual framework that integrates commensal, pathobiont, and tumor‐resident microbes into a coherent biological processor driving malignancy. 2. This study describes the dynamic shift from a homeostatic microbiome to a pathological oncobiome, detailing how diet, antibiotics, and environment ...
Xuan Zhang +6 more
wiley +1 more source
Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment. [PDF]
Li Y +13 more
europepmc +1 more source
Integrative bioinformatics‐driven discovery of novel chimeric antigen receptor (CAR)‐T cell targets in melanoma. ABSTRACT Chimeric antigen receptor (CAR) T cell therapy has shown limited success in solid tumors, mainly because of the scarcity of tumor‐specific surface antigens.
Kilian F. Juraschek +12 more
wiley +1 more source
The role and function of CTLA-4 in Sjögren's syndrome. [PDF]
Wen J, Zhang L, Xie L, Zhou D, Chen M.
europepmc +1 more source
Harnessing tumor immune checkpoints for autoimmune disease therapeutics. [PDF]
Yang H, Zhang P, Wu Y, Xie N, Shen G.
europepmc +1 more source
Assessment of Clinical and Immunological Factors of Local Recurrence in Canine Soft Tissue Sarcoma
ABSTRACT Canine soft tissue sarcomas (STSs) are locally invasive tumours, making local recurrence a major clinical challenge. Time to recurrence (TTR) and associated immune factors remain poorly characterized. This study aimed to characterize the immune microenvironment of canine STS and identify factors associated with TTR.
Kazuki Mizuta +2 more
wiley +1 more source
Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors. [PDF]
Alsina M +2 more
europepmc +1 more source

